Canada Life’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Canada Life’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,904	Closed	-$92K	–	2856
2020 Q1	$92K	Hold	1,904	–	–	﹤0.01%	2001
2019 Q4	$89K	Buy	+1,904	New	+$84.2K	﹤0.01%	2097
2019 Q3	–	Sell	-3,589	Closed	-$108K	–	2667
2019 Q2	$108K	Hold	3,589	–	–	﹤0.01%	2197
2019 Q1	$80K	Hold	3,589	–	–	﹤0.01%	2134
2018 Q4	$63K	Buy	+3,589	New	+$56.3K	﹤0.01%	2294
2018 Q2	–	Sell	-800	Closed	-$4K	–	2743
2018 Q1	$4K	Hold	800	–	–	﹤0.01%	2594
2017 Q4	$7K	Hold	800	–	–	﹤0.01%	2524
2017 Q3	$12K	Hold	800	–	–	﹤0.01%	2521
2017 Q2	$15K	Buy	+800	New	+$18K	﹤0.01%	2521

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Canada Life's RARX Position: Q2 2020 in Review

Canada Life sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,904 shares — an estimated $92K sold.

Canada Life first reported a position in RARX in Q2 2017 and held it in 9 quarters. The position peaked at $108K in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Canada Life reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Canada Life sold 1,904 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $92K.
Canada Life first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 9 quarters.
Canada Life's Ra Pharmaceuticals, Inc. Common Stock position peaked at $108K in Q2 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Canada Life's 13F filing for Q2 2020, filed 17 Aug 2020.